IL2 and atherosclerosis: These findings in experimental atherosclerosis are being translated into clinical applications, with the first ongoing double-blind, placebo-controlled phase I/II clinical trial, LILACS, aiming to assess the safety and efficacy of low-dose IL-2 in patients with stable ischemic heart disease and in patients with ACS [125].